GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avax Technologies Inc (OTCPK:AVXT) » Definitions » Debt-to-Revenue

Avax Technologies (Avax Technologies) Debt-to-Revenue : 0.00 (As of Sep. 2008)


View and export this data going back to . Start your Free Trial

What is Avax Technologies Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Avax Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2008 was $0.00 Mil. Avax Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2008 was $0.00 Mil. Avax Technologies's annualized Revenue for the quarter that ended in Sep. 2008 was $0.80 Mil. Avax Technologies's annualized Debt-to-Revenue for the quarter that ended in Sep. 2008 was 0.00.


Avax Technologies Debt-to-Revenue Historical Data

The historical data trend for Avax Technologies's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avax Technologies Debt-to-Revenue Chart

Avax Technologies Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.27 0.22 0.20 0.49 -

Avax Technologies Quarterly Data
Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avax Technologies's Debt-to-Revenue

For the Biotechnology subindustry, Avax Technologies's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avax Technologies's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avax Technologies's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Avax Technologies's Debt-to-Revenue falls into.



Avax Technologies Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Avax Technologies's Debt-to-Revenue for the fiscal year that ended in Dec. 2007 is calculated as

Avax Technologies's annualized Debt-to-Revenue for the quarter that ended in Sep. 2008 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2008) Revenue data.


Avax Technologies Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Avax Technologies's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Avax Technologies (Avax Technologies) Business Description

Traded in Other Exchanges
N/A
Address
9200 Indian Creek Parkway, Suite 200, Overland Park, KS, USA, 66210
Avax Technologies Inc is a development stage biotechnology company. The company is engaged in the development and commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. It also involved in the development and commercial readiness in the immuno-oncology arena.
Executives
Carl Spana director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Prendergast John K A director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017

Avax Technologies (Avax Technologies) Headlines

No Headlines